medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 2

<< Back Next >>

Ann Hepatol 2014; 13 (2)

Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy?

Ahuja NK, Ally WA, Caldwell SH

Language: English
References: 45
Page: 179-186
PDF size: 107.55 Kb.


ABSTRACT

A limited number of medications are typically considered for the management of hepatic encephalopathy occurring as a complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. Multiple alternative compounds aimed at disrupting ammoniagenesis are or will soon be available, though their use tends to be limited by a lack of large data sets and of clinical awareness. In this review, we provide a targeted overview of the mechanisms and availability of five anti-ammoniagenic compounds (sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, L-ornithine L-aspartate, and ornithine phenylacetate) identified as possibly useful alternative therapeutic agents for cirrhotic encephalopathy. Three of these medications have been FDA approved for use in congenital urea cycle disorders only, while two are under active investigation for use in cirrhotic patients. In spite of limitations posed by cost and comorbidities, familiarity with these options may prove beneficial in cases refractory to conventional management.


REFERENCES

  1. Rosch J, Keller FS. Transjugular intrahepatic portosystemic shunt: present status, comparison with endoscopic therapy and shunt surgery, and future prospectives. World J Surg 2001; 25: 337-45; discussion 345-6.

  2. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41(2): 386-400.

  3. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Biel AT. Hepatic encephalopathy-Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.

  4. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, et al. Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene- Covered Stent Grafts. Am J Gastroenterol 2008; 103: 2738-46.

  5. Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, Wu K, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol 2011; 26: 943-51.

  6. Kappus MR, Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. Clin Gastroenterol Hepatol 2012; 10: 1208-19.

  7. Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res 2013.

  8. Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006; 55(11): 1617-23.

  9. Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. Journal of Hepatology 2005; 42: 674-9.

  10. Bai M, Han G, Qi X, Yin Z, Fan D. Two hypotheses for decreasing hepatic encephalopathy risk after transjugular intrahepatic portosystemic shunt. Hepatology 2010; 51: 2236-7.

  11. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004; (2)(2):CD003044.

  12. Huang E, Esrailian E, Spiegel BMR. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther 2007; 26(8): 1147-61.

  13. D’Amico G, Luca A. TIPS is a cost effective alternative to surgical shunt as a rescue therapy for prevention of recurrent bleeding from esophageal varices. J Hepatol 2008; 48: 387-90.

  14. Jones EA, Mullen KD. Theories of the Pathogenesis of Hepatic Encephalopathy. Clinics in Liver Disease 2012; 16: 7-26.

  15. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.

  16. Damink SWMO, Jalan R, Redhead DN, Hayes PC, Deutz NEP, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-71.

  17. Crespin J, Nemcek A, Rehkemper G, Blei AT. Intrahepatic portal-hepatic venous anastomosis: a portal-systemic shunt with neurological repercussions. Am J Gastroenterol 2000; 95: 1568-71.

  18. Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridol L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012; 16: 133-46.

  19. Romero-Gomez M, Jover M, Diaz-Gomez D, de Teran LC, Rodrigo R, Camacho I, Echevarria M, et al. Phosphateactivated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. World J Gastroenterol 2006; 12: 2406-11.

  20. Phongsamran PV, Kim JW, Abbott JC, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs 2010; 70(9): 1131-48.

  21. Wright G, Noiret L, Damink SWO, Jalan R. Interorgan ammonia metabolism in liver failure: The basis of current and future therapies. Liver International 2011; 31(2): 163-75.

  22. Smith I. The treatment of inborn errors of the urea cycle. Nature 1981; 291(5814): 378-80.

  23. Buphenyl [package insert]. Ucyclyd Pharma, Inc., Scottsdale, AZ: April 2009. http://pi.medicis.us/buphenyl.pdf. Accessed 27 January 2013.

  24. McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, Gargosky S, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51(6): 2077-85.

  25. Ravicti [prescribing information]. Hyperion Therapeutics, Inc. San Francisco, CA: January 2013. http://www.ravicti.com/files/ RAVICTI_Prescribing_Information.pdf. Accessed 7 February 2013.

  26. Rockey DC, Vierling JM, Mantry PS, Ghabril M, Brown RS, Alexeeva O, Zupanets IA, et al. Randomized, controlled, double blind study of glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy. The Liver Meeting 2012; November 9-13, 2012; Boston, MA. AASLD; 2012.

  27. Jover-Cobos M, Noiret L, Sharifi Y, Jalan R. Ornithine phenylacetate revisited. Metabolic Brain Disease 2013: 1-5.

  28. Jiang Q, Jiang X-H, Zheng M-H, Chen Y-P. l-Ornithine-l-aspartate in the management of hepatic encephalopathy: A meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.

  29. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, Hendricks R, et al. Therapeutic efficacy of L-ornithine- L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 1997; 25(6): 1351-60.

  30. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: A double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136(7): 2159-68.

  31. Jalan R, Wright G, Davies NA, Hodges SJ. L-ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69(5): 1064-9.

  32. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of l-ornithine-l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47: 571-4.

  33. Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, Jalan R. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver International 2012; 32: 410-19.

  34. Oria M, Romero-Giménez J, Arranz JA, Riudor E, Raguer N, Cordoba J. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis. J Hepatol 2012; 56: 109-14.

  35. Ventura-Cots M, Simon-Talero M, Torrens M, Arranz JA, Riudor E, Blanco A, Cordoba J. Effects of ornithine phenylacetate in patients with cirrhosis and upper gastrointestinal bleeding: an open-label, dose-escalating, single cohort study. The Liver Meeting 2012; November 9-13, 2012; Boston, MA. AASLD; 2012.

  36. Ocera Therapeutics, Inc. (2010.) Ocera therapeutics completes first in human studies with OCR-002 for the treatment of hyperammonemia and hepatic encephalopathy [press release]. http://www.prnewswire.com/ news-releases/ocera-therapeutics-completes-firstin- human-studies-with-ocr-002-for-the-treatmentof- hyperammonemia-and-hepatic-encephalopathy-111913229.html. Accessed 27 January 2013.

  37. Hassanein T, Kittrelle J, Cato J, Fischer L, Anderson K. A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) in patients with stable hepatic cirrhosis. The Liver Meeting 2011; November 4-8, 2011: San Francisco, CA. AASLD; 2011.

  38. Batshaw ML, Brusilow S, Waber L, Blom W, Brubakk AM, Burton BK, Cann HM, et al. Treatment of inborn errors of urea synthesis. N Engl J Med 1982; 306(23): 1387-92.

  39. Sushma S, Dasarathy S, Tandon RK, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992; 16(1): 138-44.

  40. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 2000; 95: 3574-8.

  41. Palekar AG, Canas JA, Kalbag SS, Kim S-J, Castro-Magana M, Angulo MA. Failure of sodium benzoate to alleviate plasma and liver ammonia in rats. Biochem Med Metab Biol 1989; 41: 64-9.

  42. Campollo O, Gil S, Olvera G, Poo JL, Uribe M. Efficacy and safety of sodium benzoate for the long term treatment of chronic hyperammonemic hepatic encephalopathy (CHPSE). Annual Meeting of the AASLD 1992; October 31-November 3, 1992: Chicago, IL. AASLD; 1992.

  43. Ammonul [package insert]. Ucyclyd Pharma, Inc., Scottsdale, AZ: June 2011. http://pi.medicis.us/ammonul.pdf. Accessed 27 January 2013.

  44. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007; 356(22): 2282-9.

  45. Mendenhall CL, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986; 81: 540-3.




2020     |     www.medigraphic.com